GW Pharmaceuticals to Present at the Goldman Sachs 39th

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
815
GW Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

LONDON and CARLSBAD, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH ) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 10:00 a.m. PT at the Terranea Resort, in Rancho Palos Verde, CA.

A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com . A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc and Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. and Europe for the adjunctive treatment of Lennox-Gastaut syndrome and Dravet syndrome. The Company continues to evaluate Epidiolex in additional rare epilepsy conditions and currently has an ongoing clinical trial in Tuberous Sclerosis Complex. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a US Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com .

Enquiries:

GW Pharmaceuticals plc  
Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500 6570
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 24

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 19

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 16

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 27

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 24

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 11

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 28

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

Huawei eKit Unveils Over 30 Innovative Products to Boost Partners

Updated Category News Views 169

Huawei eKit Launches New Innovative Solutions In a groundbreaking event, Huawei showcased its commitment to supporting the growth of its partners in the distribution business. The recent forum revealed an impressive array of over 30 new products designed to enhance the competitiveness of Huawei eKit and facilitate the digital transformation journeys of small and medium...

Continue Reading
EDAP TMS Strengthens Board with Joshua H. Levine's Appointment

Updated Category News Views 161

EDAP TMS Welcomes Joshua H. Levine to Board of Directors EDAP TMS SA (Nasdaq: EDAP), a recognized leader in robotic energy-based therapies, has made a significant addition to its Board of Directors with the appointment of Joshua H. Levine. This strategic move marks a pivotal moment for the company as it continues to strengthen its position within the medical technology...

Continue Reading
Salama's Impressive H1 2025 Growth Highlights Financial Stability

Updated Category News Views 233

Salama's Remarkable Financial Growth in H1 2025 Salama (DFM: "SALAMA"), one of the leading Takaful providers in the region, has recently announced substantial financial results for the first half of 2025. The company reported a net profit of AED 8.25 million, demonstrating its commitment to operational excellence and sustainability. Profitability Driven by Strong Q2...

Continue Reading
Navigating the Rise of Intraoral Scanners in Modern Dentistry

Updated Category News Views 353

Understanding the Growth of Intraoral Scanners The global intraoral scanners market is experiencing a remarkable transformation, projecting a leap from US$ 786.5 million in 2024 to a staggering US$ 1,798.8 million by 2033. This growth signals a compound annual growth rate (CAGR) of 9.6% between 2025 and 2033, indicating a significant shift towards digital solutions in...

Continue Reading
Revolutionizing Risk Management: Oscilar's Innovative AI Agents

Updated Category News Views 129

Revolutionizing Risk Management with AI Oscilar Launches Revolutionary Agentic AI Platform Transforming Risk Decisioning Oscilar, the leading innovator in AI-driven risk management, has announced the launch of its groundbreaking AI Agent platform, reshaping how organizations manage online risk. Built around a network of specialized AI agents, Oscilar's platform addresses...

Continue Reading